Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.60 |
| ▸ | PI4KA | P42356 | 11/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 11/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 11/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28873718 | 0.98 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL580610 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27570467 | 0.76 | PI4KA (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8284838 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1370892 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL106573 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8069211 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9074153 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | claimed |
| CN-111269876-A | Method for in vitro fertilization and embryo culture by in vivo collection of bovine oocytes | 天津博裕力牧科技有限公司 | 2020-06-12 | — | — | CN | claimed |
| CN-105968156-B | A kind of αisomer impurity of Rui Jianuosheng and its preparation method and application | 南京海融医药科技股份有限公司 | 2019-05-24 | — | — | CN | claimed |
| CN-106170553-A | Modified nucleic acid molecules and uses thereof | 现代治疗公司 | 2016-11-30 | — | — | CN | claimed |
| CN-102311472-B | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-adenine | SCINOPHARM KUNSHAN BIOCHEMICAL TECHNOLOGY CO LTD | 2014-09-03 | — | — | CN | claimed |
| CN-118165044-A | Stereoselective synthesis method and application of alpha-2' -deoxynucleoside | 中国药科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023091768-A1 | CELL-POTENT BISUBSTRATE INHIBITORS FOR NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-112266386-B | 2-chloroadenine derivative, preparation method and application | 中山大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-110402249-A | Extracellular nucleotides enzyme inhibitor and its application method | CALITHERA BIOSCIENCES INC | 2019-11-01 | — | — | CN | disclosed |
| CN-110234656-A | Extracellular nucleotides enzyme inhibitor and its application method | 卡利泰拉生物科技公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-3510040-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096233-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1444335-A2 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB Research Foundation (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1412369-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | Ilex Oncology, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6680382-B2 | COUPLING ADENINE DERIVATIVE WITH BLOCKED ARABINOFURANOSYL DERIVATIVE TO FORM 2-CHLORO-9-(2'-DEOXY-2'-FLUORO-B-ARABINOFURANOSYL)ADENINE; ANTICANCER AGENTS; VIRICIDES | ILEX PRODUCTS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030114663-A1 | Process for preparing purine nucleosides | GENZYME CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003035012-A2 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB RESEARCH FOUNDATION (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003011877-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114663-A1 | Process for preparing purine nucleosides | SAMHD1, APRT, NUDT1 | ADORA2A 50/4885ADORA1 68/4885PI4KA 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.